SHARx: Drug Pricing Isn’t Just Broken, It’s Protected

Growing regulatory scrutiny and industry reporting suggests that high drug prices persist not just because of cost, but because of a system designed to protect pricing benchmarks, according to industry insider, Paul Pruitt of SHARx. As lower-cost, clinically viable alternatives emerge, they threaten to reset expectations—and disrupt the economics of the pharmaceutical market.